PCR88 Explaining psychiatric comorbidities in patients with skin conditions: the importance of clinical characteristics and patient-reported disease impact [Abstract]

FitzGerald, Allison, da Silva Burger, Neuza, Pattinson, Rachael ORCID: https://orcid.org/0000-0002-3145-3710, Trialonis-Suthakharan, Nirohshah, Austin, Jennifer, Bundy, Chris and Augustin, Matthias 2025. PCR88 Explaining psychiatric comorbidities in patients with skin conditions: the importance of clinical characteristics and patient-reported disease impact [Abstract]. Presented at: ISPOR Europe 2025: Powering Value and Access Through Patient-Centered Collaboration, Glasgow, UK, 9-12 November 2025. Value in Health. , vol.28 (12, S1) Elsevier, S564. 10.1016/j.jval.2025.09.2561

Full text not available from this repository.

Abstract

Objectives The prevalences for depression and anxiety disorders are estimated at 3.8% and 4% of the global population; however, these can ascend to 30% in dermatology patients. This study aimed to contribute to explain these high rates of psychiatric comorbidity by examining the associations between clinical variables, disease impact, and mental health. Methods An online survey, available in 17 different languages, was conducted between June 2023 and January 2024. Adults with a self-reported dermatological condition were recruited through patient organizations and social media. Participants completed the Patient-Reported Impact of Dermatological Diseases (PRIDD; 16 items assessing physical, life responsibilities, psychological and social impact domains), the Patient Health Questionnaire (PHQ-9), the General Anxiety Disorder Assessment (GAD-7), and provided sociodemographic and clinical information. Hierarchical regression analyses were conducted to identify sociodemographic characteristics, clinical variables and impact domains associated with depression and anxiety. Results 3680 participants were included, 76.4% female, mean age of 48.7±15.7 years, from 87 different countries, and across 114 dermatological conditions (e.g., 12.8% Lichen Sclerosus, 12.3% Psoriasis, 8.2% Hidradenitis Suppurativa). 1349 (36.7%) respondents scored above the threshold for clinical depression (PHQ-9≥10) and 956 (26.0%) for clinical anxiety (GAD-7≥10). Sociodemograhic characteristics (younger age, female sex) explained 3.9% and 5.2% of the variance in depression and anxiety scores, respectively. Clinical variables explained 20.1% of depression and 15.0% of anxiety scores: rare diseases, higer disease severity, presence of comorbidities, and lower satisfaction with current healthcare were associated with higher scores for both depression and anxiety; besides, being member of a patient organization was associated with lower levels of anxiety. PRIDD dimensions (higher physical, psychological and social impact; lower life responsibilities impact) explained an additional variance of 22.6% for depression and 22.8% for anxiety. Conclusions These results emphasize the importance of capturing the multidimensional burden of skin conditions on patients’ lives, as a significant risk factor for psychiatric comorbidities.

Item Type:	Conference or Workshop Item - published (Other)
Date Type:	Publication
Status:	Published
Schools:	Schools > Healthcare Sciences
Publisher:	Elsevier
ISSN:	1098-3015
Last Modified:	20 Jan 2026 13:48
URI:	https://orca.cardiff.ac.uk/id/eprint/183956

Actions (repository staff only)

Edit Item